THERAPEUTIC USE OF NEW PHARMACEUTICAL PREPARATIONS CONTAINING ANTITUMORAL DRUGS BOUND TO HYALURONIC ACID IN THE TREATMENT OF NEOPLASIAS

摘要

The present invention describes the new use in the oncologic field ofbioconjugates as differentiating agentsob-tained by the conjugation between hyaluronic acid (HA) and achemotherapeutic product (identified hereafter with the trade-nameONCOFID®) among which, in particular, Irinotecan, Doxorubicin, Paclitaxel,Cis-platinum and 5-Fluorouracyl (5-FU) fortreat-ing primary tumors and metastasis. In particular, the biologicalbehaviour is described in terms of action mechanism, efficacy andtolerability of pharmaceutical preparations of derivative of ONCOFID®soluble in water. More specifically, the invention relatesto the surprising biological and pharmacological effect demonstrated byformulations based on ONCOFID-S (HA-SN38conju-gates) and ONCOFID-D (HA-Doxorubicin conjugates) in promoting thedifferentiation of tumoral cells towards a untransformedphenotype, compared with the reference drug Irinotecan (or CPT11 whose activeform is represented by SN38) and Doxorubicin.